UniQure (QURE) Announces Proposed $150 Million Public Offering

UniQure (QURE) announced on June 23, 2026, a proposed public offering of $150 million in common shares. The biotechnology company intends to use the proceeds primarily to fund general corporate purposes, including ongoing research and development efforts for its gene therapy pipeline. The offering is expected to result in dilution for current shareholders. J.P. Morgan, Leerink Partners, and Piper Sandler are acting as joint book-running managers for the proposed offering. Underwriters will also have a 30-day option to purchase up to an additional $22.5 million of UniQure's common shares. Proceeds will specifically support the clinical development of UniQure's gene therapies, including AMT-130 for Huntington's disease and AMT-260 for refractory mesial temporal lobe epilepsy. The completion and terms of the offering remain subject to market conditions.